Status:
COMPLETED
Diagnostic Usefulness of Fluorine-18-α-Methyltyrosine PET in Combination With 18F-FDG in Sarcoidosis Patient
Lead Sponsor:
Gunma University
Conditions:
Sarcoidosis
Eligibility:
All Genders
Brief Summary
L-\[3-18F\]-α-methyltyrosine (FMT) is amino-acid tracer for positron emission tomography (PET), and is used for tumor detection because malignant tumor cells accumulate 18F-FMT based on the increased ...
Eligibility Criteria
Inclusion
- Eligible patients were required to have histologically proven noncaseating epithelioid cell granuloma and at least one disease that the possibility of coexistent malignancy could not be excluded as follows; 1) extrapulmonary lesions mimicking malignant diseases including systemic lymphadenopathy, hepatosplenic involvement, or other lesions, 2) multiple nodular lesions mimicking pulmonary metastasis, 3) the occurrence of BHL in cancer patient.
Exclusion
- The patients that PET imaging using 18F-FDG and 18F-FMT was performed before establishment of the final diagnosis of sarcoidosis, patients undergoing treatment for sarcoidosis before the PET study, and patient having diabetes mellitus.
Key Trial Info
Start Date :
September 1 1998
Trial Type :
OBSERVATIONAL
End Date :
August 1 2005
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00369980
Start Date
September 1 1998
End Date
August 1 2005
Last Update
November 7 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gunma University Graduate School of Medicine
Gunma, Japan, 371-8511